PEN
THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care
Article Summary
HOLD- Penumbra Inc. (NYSE: PEN) announced the results of THUNDER, an Investigational Device Exemption study to evaluate safety and effectiveness of its novel computer-assisted vacuum-assisted thrombectomy (CAVT) system in stroke patients with emergent large vessel occlusion, with 87.5% of cases achieving successful successful reperfusion, defined as mTICI 2b-3 after treatment with THUNERBOLT, with post-THUNDER post-reperfusion achieved 70.4% of the time, associated with significantly better functional recovery and lower complication rates.
- The first and only CAVT device for stroke demonstrated high revascularization rates, short procedure times, and low complication rates, with modulated aspiration facilitating consistent and complete clot removal when used in conjunction with standard-sized aspiration catheters.
- The study enrolled 216 patients across 29 U.S. centers and met its predefined performance goal, demonstrating a high rate of complete clot ingestion and a low rate of complications.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 17.3% | 25% | 60.0 ptsModerate (17.3%) - Decent growth |
| EPS Growth Next 5Y ? | 23.8% | 25% | 70.0 ptsGood (23.8%) - Solid outlook |
| Target Price Upside ? | 15.1% | 20% | 60.0 ptsModerate Upside (15.1%) - Target: $364.25 vs Current: $316.50 |
| Gross Margin % ? | 66.6% | 15% | 80.0 ptsVery Healthy (66.6%) - High-quality margins |
| Drawdown from 52-Wk High ? | -12.7% | 15% | 40.0 ptsMild Pullback (-12.7%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About PEN
- Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.
- It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
- It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands.
- In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products.
- Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum.
- It sells its products through direct sales organizations and distributors.
- The company was incorporated in 2004 and is based in Alameda, California.